Trump Considers Dismissal of FDA Chief Amid Rising Controversy

Want the full story?
Read the complete article at KVIA
AI Summary
President Donald Trump has approved a plan to potentially remove FDA Commissioner Dr. Marty Makary due to increasing criticism regarding his management of the agency, particularly concerning drug approvals and access to the abortion pill mifepristone. Although no formal dismissal has occurred yet, pressure from anti-abortion activists and pharmaceutical industry officials has intensified, leading to discussions about Makary's job security. The FDA is currently without a permanent director for the CDC and a surgeon general, which adds to the instability within the health department as midterm elections approach. The situation highlights the ongoing tensions within the administration regarding health policies and their implications for abortion access nationwide.
Key Details: • Trump's decision on Makary's dismissal is pending, with no formal action taken yet. • A meeting with anti-abortion activists is scheduled for Friday evening. • Medication abortion now accounts for about two-thirds of all US abortions. • The Supreme Court may soon decide on a case affecting mail orders of abortion pills.